Literature DB >> 10854571

3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.

I Lamensdorf1, G Eisenhofer, J Harvey-White, A Nechustan, K Kirk, I J Kopin.   

Abstract

3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine. This aldehyde is mainly oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH), but is also partly reduced to 3, 4-dihydroxyphenylethanol (DOPET) by aldehyde or aldose reductase (ARs). In a previous study, we found that rotenone, a complex I inhibitor, induced a rapid accumulation of DOPAL and DOPET in the medium of cultured PC12 cells. Here, we examined the potential role of DOPAL in the toxicity induced by complex I inhibition in PC12 cells and compared the effects of rotenone on concentrations of DOPAL and DOPET to those of MPP(+). DOPAL and DOPET levels were increased by rotenone but decreased by MPP(+). Inhibition of ALDH by daidzein reduced the formation of DOPAC and increased the accumulation of DOPAL. Inhibition of ARs (with AL1576) diminished DOPET formation and elevated DOPAL concentrations. Combined inhibition of ALDH and ARs markedly elevated DOPAL concentrations while diminishing DOPET and DOPAC levels. The elevation of DOPAL levels induced by combined inhibition of ALDH and ARs had no effect on cell viability. However, combined inhibition of ALDH and ARs potentiated rotenone-induced toxicity. Both the potentiation of toxicity and the increase in DOPAL levels were blocked by inhibition of monoamine oxidase with clorgyline indicating that accumulation of DOPAL was responsible for the potentiated rotenone-induced toxicity following combined inhibition of ALDH and ARs. Since complex I dysfunction is reported to be involved in the pathogenesis of Parkinson's disease, DOPAL potentiation of the deleterious effects of complex I inhibition may contribute to the specific vulnerability of dopaminergic neurons to injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854571     DOI: 10.1016/s0006-8993(00)02309-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  28 in total

1.  Catechols in post-mortem brain of patients with Parkinson disease.

Authors:  D S Goldstein; P Sullivan; C Holmes; I J Kopin; M J Basile; D C Mash
Journal:  Eur J Neurol       Date:  2010-11-12       Impact factor: 6.089

2.  Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis.

Authors:  Lina Yao; Peidong Fan; Maria Arolfo; Zhan Jiang; M Foster Olive; Jeff Zablocki; Hai-Ling Sun; Nancy Chu; Jeongrim Lee; Hee-Yong Kim; Kwan Leung; John Shryock; Brent Blackburn; Ivan Diamond
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

3.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

4.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

5.  Polychlorinated biphenyls and polybrominated diphenyl ethers alter striatal dopamine neurochemistry in synaptosomes from developing rats in an additive manner.

Authors:  Anne Dreiem; Richard J Okoniewski; Karl O Brosch; Veronica M Miller; Richard F Seegal
Journal:  Toxicol Sci       Date:  2010-07-29       Impact factor: 4.849

Review 6.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

7.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

8.  Biochemical characterization of the catecholaldehyde reactivity of L-carnosine and its therapeutic potential in human myocardium.

Authors:  Margaret-Ann M Nelson; Zachariah J Builta; T Blake Monroe; Jonathan A Doorn; Ethan J Anderson
Journal:  Amino Acids       Date:  2018-09-06       Impact factor: 3.520

Review 9.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

10.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.